Answers are grounded in this paper and cite their sources.
Introduction and objective: B and T acute lymphoblastic leukemias (ALL) are the most common malignancies in children. In recent years, thanks to advances in the field of pharmacology and genetics, the 5-year survival rate for children and adolescents suffering from ALL has improved to more than 90%. However, because of toxicities and adverse effects of current treatment, the incorporations of novel therapeutic approaches are needed to enhance the quality of life of patients. Recent studies reveal that amygdalin is a potent inhibitor of cell growth in bladder, breast, pancreatic, prostate cancer, and renal cell carcinoma cell lines. The aim of the study is to assess the influence of amygdalin on the expression of different genes in B and T acute lymphoblastic leukemia cell lines. Material and methods: B-ALL CCRF-HSB-2 [CCRF HSB-2, HSB-2] CCL-102.1 cell line and T- ALL CCRF-SB [CCRF-SB] CCL120 cell line were cultured and treated with amygdalin in concentration of 5 mg/ml and 10 mg/ml. Clariom S human array was used to evaluate the expression of genes. Microarray data were analyzed using Transcriptome Analysis Console 4.0, following the TAC user guide. Results: The results show that exposing tumour cells of T- ALL CCRF-SB cell line to amygdalin led to down-regulation in concentration-dependent manner a.o. of MYC, BCL2, ID1, HRAS, NOTCH1 pathway, PI3K/AKT pathway. In stimulated with amygdalin B-ALL CCRF-HSB-2 cell line downregulation of a.o. CRKL and EZH2 genes was observed. Conclusions: The study provides the first insight into the potential influence of amygdalin on childhood acute lymphoblastic leukemia cell lines.
No takes yet. Share an insight, caveat, or question.
Wojciechowska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: